Armata Pharmaceuticals is classified as operating in the Medicinal & Botanical Manufacturing industry, NAICS Code 325411.
Trademark Applications
Trademark applications show the products and services that Armata Pharmaceuticals is developing and marketing.
Armata Pharmaceuticals doesn't have any recent trademark applications, indicating Armata Pharmaceuticals is focusing on
its existing business rather than expanding into new products and markets.
Trademarks may include brand names, product names, logos and slogans.
Trademark
Date
ARMATA PHARMACEUTICALS Targeted, pathogen-specific antimicrobial pharmaceutical preparations for the treatment of bacterial and fungal mediated infectious diseases as well as microbial dysbiosis associated with human disease
01/29/2019
C3J THERAPEUTICS Targeted, pathogen-specific antimicrobial pharmaceutical preparations for the treatment of bacteria and fungal mediated diseases and disorders caused by microbial dysbiosis
10/12/2015
See all trademarks and details in the Full Report.
Market Share of Armata Pharmaceuticals's Largest Competitors
A competitive analysis shows these companies are in the same general field as Armata Pharmaceuticals, even though they may not compete head-to-head.
These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines.
The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies.
Competitive advantage comes from offering better pricing or superior products/service.
These companies are similar in business line and location to Armata Pharmaceuticals.
While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.
Future Competition: Armata Pharmaceuticals's Fastest Growing Competitors
These companies are in the same general field as Armata Pharmaceuticals and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.